Zenith Drugs Complete Financial Statements

In FYNone, Zenith Drugs (ZENITHDRUG) reported revenue ₹0 Cr, net profit ₹0 Cr and EPS ₹0.00, with a net profit margin of 7.5% and ROE of 16.1%. Full financial statements from FY2022 to FY2024 (3 years) — income statement, balance sheet and cash flow in ₹ Crores. Download as Excel or CSV. For live price, earnings ratios and company overview, see ZENITHDRUG stock overview.

3 Years of Data
2024 - 2022

Complete Financial Data Export

Profitability Ratios

Net Profit Margin 7.46% 2024 data
EBITDA Margin 14.18% 2024 data
Operating Margin 13.00% 2024 data
Return on Assets 7.41% 2024 data
Return on Equity 16.13% 2024 data

Balance Sheet Ratios

Current Ratio 12.56 2024 data
Equity Ratio 45.93% 2024 data
Asset Turnover 0.99 2024 data

ZENITHDRUG Revenue, Net Profit & EBITDA — Year-on-Year Growth

ZENITHDRUG YoY (March 2024 vs Period) — revenue -100.0%, net profit -100.0%, EBITDA -100.0%, expenses -100.0%.

Revenue Growth
-100.0%
Year-over-Year
Net Profit Growth
-100.0%
Year-over-Year
EBITDA Growth
-100.0%
Year-over-Year
Expense Growth
-100.0%
Year-over-Year
Assets Growth
+37.8%
Year-over-Year
Equity Growth
+244.4%
Year-over-Year
Operating Cash Flow Growth
-160.0%
Year-over-Year
Financing Cash Flow Growth
-200.0%
Year-over-Year

ZENITHDRUG Income Statement — Revenue, EBITDA & Net Profit

Zenith Drugs revenue ₹0 Cr, EBITDA ₹0 Cr, net profit ₹0 Cr, EPS ₹0.00 (None) — net profit margin 7.5%. Explore Zenith Drugs intrinsic price to estimate fundamental worth using multiple valuation models.

Periods ₹ Crores
Particulars None March 2024 March 2023 March 2022
Revenue 0 134 116 93
Expenses 0 115 106 85
EBITDA 0 19 10 8
Operating Profit Margin % 0.00% 13.00% 8.00% 7.00%
Depreciation 0 1 1 1
Interest 0 3 2 2
Profit Before Tax 0 13 7 4
Tax 0 4 2 1
Net Profit 0 10 5 3
Earnings Per Share (₹) 0.00 5.63 122.02 78.22

ZENITHDRUG Balance Sheet — Assets, Liabilities & Shareholders' Equity

ZENITHDRUG total assets ₹135 Cr, total equity ₹62 Cr, total liabilities ₹ Cr (2024) — ROE 16.1%.

Years Annual Data ₹ Crores
Particulars 2024 2023 2022
ASSETS
Total Assets 135 98 69
Current Assets 113 84 54
Fixed Assets 11 12 11
Capital Work in Progress 4 0 3
Investments 0 0 0
Other Assets 120 86 55
LIABILITIES
Total Liabilities
Current Liabilities 9 9 10
Non-Current Liabilities
SHAREHOLDERS' EQUITY
Total Equity 62 18 12
Share Capital 17 0 0
Reserves & Surplus 45 17 12

ZENITHDRUG Cash Flow Statement — Operating, Investing & Financing

Zenith Drugs operating cash flow ₹-13 Cr, investing ₹26 Cr, financing ₹-5 Cr, net cash flow ₹9 Cr (2024).

Periods ₹ Crores
Particulars March 2024 March 2023 March 2022
Operating Activities -13 -5 5
Investing Activities 26 0 -5
Financing Activities -5 5 1
Net Cash Flow 9 0 1